Technical Analysis for ALRN - Aileron Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 2.87 -10.31% -0.33
ALRN closed down 10.31 percent on Friday, September 21, 2018, on 62 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ALRN trend table...

Date Alert Name Type % Chg
Sep 21 Fell Below 20 DMA Bearish 0.00%
Sep 21 Fell Below 50 DMA Bearish 0.00%
Sep 21 Wide Bands Range Expansion 0.00%
Sep 20 50 DMA Support Bullish -10.31%
Sep 20 Inside Day Range Contraction -10.31%
Sep 20 Wide Bands Range Expansion -10.31%
Sep 19 50 DMA Support Bullish -15.34%
Sep 19 MACD Bullish Centerline Cross Bullish -15.34%
Sep 19 Pocket Pivot Bullish Swing Setup -15.34%
Sep 19 Doji - Bearish? Reversal -15.34%

Older signals for ALRN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Is ALRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.48
52 Week Low 1.98
Average Volume 109,103
200-Day Moving Average 6.3651
50-Day Moving Average 3.1112
20-Day Moving Average 2.9965
10-Day Moving Average 3.012
Average True Range 0.3952
ADX 26.69
+DI 27.088
-DI 20.8023
Chandelier Exit (Long, 3 ATRs ) 2.9144
Chandelier Exit (Short, 3 ATRs ) 3.2756
Upper Bollinger Band 3.8386
Lower Bollinger Band 2.1544
Percent B (%b) 0.42
BandWidth 56.205573
MACD Line 0.0195
MACD Signal Line -0.0107
MACD Histogram 0.0302
Fundamentals Value
Market Cap 42.23 Million
Num Shares 14.7 Million
EPS -41.73
Price-to-Earnings (P/E) Ratio -0.07
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.61
Resistance 3 (R3) 3.69 3.52 3.48
Resistance 2 (R2) 3.52 3.34 3.48 3.44
Resistance 1 (R1) 3.20 3.22 3.12 3.12 3.40
Pivot Point 3.03 3.03 2.99 2.99 3.03
Support 1 (S1) 2.71 2.85 2.63 2.63 2.34
Support 2 (S2) 2.54 2.73 2.50 2.30
Support 3 (S3) 2.22 2.54 2.26
Support 4 (S4) 2.14